Kolkata News Today

Extended Oral Antibiotics Market foreseen to grow exponentially over 2021-2031

 Breaking News
  • No posts were found

Extended Oral Antibiotics Market foreseen to grow exponentially over 2021-2031

July 28
20:50 2021
Extended Oral Antibiotics Market foreseen to grow exponentially over 2021-2031

Extended Oral Antibiotics Market
Extended Oral Antibiotics Market Projects to Flourish in Germany During the Forecast Period 2021 – 2031

Extended oral antibiotics are one of the effective approach to prevent or control prosthetic joint infections, but the timing of delivery to optimize patient outcomes are debated. The other name for prosthetic joint infection (PJI) is peri-prosthetic infection, an infection involving the adjacent tissues and joint prosthesis. Prosthetic joint infection is one of the common etiologies and complications of implant failure after joint replacement surgeries and is putting a financial burden on the global healthcare system, and significant psychological and physical morbidity on patients. The majority of prosthetic joint infection (PJI) occurs within one year of surgery and are initiated through the introduction of microorganisms during the surgery, caused through either direct contact or aerosolized contamination of the periprosthetic tissue or prosthesis.

The use of extended oral antibiotics has been found effective in minimizing the rate of prosthetic joint infections. It was observed that the prosthetic joint infections rate in high-risk patients who received antibiotics was less than the rate observed in low-risk patients. Thus, the extended oral antibiotic treatment may be an effective measure to prevent poor host factors. The rising number of total joint (hip (THA) and knee (TKA)) arthroplasty coupled with the growing advancements in novel therapies are expected to boost the global extended oral antibiotics market during the forecast period.

 

Request a Report Sample to Gain Valuable Insights at https://www.factmr.com/connectus/sample?flag=S&rep_id=5630

 

What are the factors boosting the Growth of the Extended Oral Antibiotics Market?

Extended oral antibiotics is likely to foster significant demand in the market due to the rising number of total joint arthroplasties (hip (THA) and knee (TKA) arthroplasty) and cases of prosthetic joint infections. Furthermore, the rising advancements in R&D for preventing or controlling prosthetic joint infections and introduction of immunoparticles, nanoparticles, novel antibiotics, photodynamic therapy, antimicrobial peptides, and lytic bacteriophages are some of the factors driving the growth of the global extended antibiotics market. Furthermore, the increasing geriatric population and antibiotics resistance is leading to the development of new antibiotics, which adds another factor driving the extended oral antibiotics market growth.

The approaching reimbursement scenario is expected to have a positive impact on the extended oral antibiotics market growth. The government is the primary payer for the majority of total joint arthroplasties, through Medicare spending. Furthermore, in addition to improving patient care, preventing prosthetic joint infections may save costs to the Medicare plans. Several strategies and reimbursements are on the horizon that will impact provider compensation for hospitals and physicians.

 

What are the Key Challenges that may restrain the Growth of the Extended Oral Antibiotics Market

However, there are some factors that can hinder the growth of global extended oral antibiotics market growth such as lack of trained pathologist in performing the histological analysis, especially in poor countries and awareness of the disease diagnosis treatment. Furthermore, the stringent regulations and lack of FDA approvals in some regions may impact the global extended oral antibiotics market growth.

 

Key Segments of Extended Oral Antibiotics Market Covered in the Report

Based on drug type, the global extended oral antibiotics market has been segmented as

• Rifampin

• Ciprofloxacin

• Penicillin

• Ampicillin

• Others

 

Based on distribution channel, the global extended oral antibiotics market has been segmented as

• Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies

• Others

 

For entire list of market players, request for TOC here – https://www.factmr.com/connectus/sample?flag=RM&rep_id=5630

 

Competitive Landscape

Key players such as

• Arrevus, Melinta Therapeutics Inc.

• Nabriva Therapeutics plc

• Peptilogics Inc.

• elephus Medical LLC

others are actively involved in offering extended oral antibiotics.

 

How Increasing R&D to Augment Extended Oral Antibiotics Market Growth?

The rising demand for preventing or controlling prosthetic joint infection is encouraging key manufacturers to invest more in research activities to develop more extended oral antibiotics. Manufacturers are engaged in clinical trials for drug compounds to develop extended oral antibiotics. Few of them have got the FDA approval from the regulatory bodies.

For example, Lefamulin (IV/Oral) compound of Nabriva Therapeutics plc, is in Phase I of clinical trial for the indications including prosthetic joint infection and osteomyelitis.

Moreover other players including Telephus Medical LLC and Melinta Therapeutics, Inc. have their compounds under pipeline for the treatment. This is one of the prime factor driving the growth of the global extended oral antibiotics market.

 

What strategies are the Key Players adopting for Increasing their Market Share in the Extended Oral Antibiotics Market?

The extended oral antibiotics market is set to change in the coming years, owing to the rising awareness of the prosthetic joint infections after hip (THA) and knee (TKA) arthroplasty. Furthermore, the favorable environment for new anti-infective modalities is expected to expand the size of the global extended oral antibiotics market by promoting the manufacturers to penetrate more into the market. The major players are working to assess challenges and seek opportunities that could influence extended oral antibiotics R&D. The therapies under development are focused on novel approaches to treat the prosthetic joint infections condition. Launch of emerging therapies will significantly impact the global extended oral antibiotics market.

 

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. We are headquartered in Dubai, and operate from our sales office in Dublin, Ireland. Reach out to us with your goals, and we’ll be an able research partner.

Media Contact
Company Name: Fact.MR
Contact Person: Neha Bhosle
Email: Send Email
Phone: 6282511583
Address:US Sales Office: 11140 Rockville Pike
City: Rockville
State: Maryland
Country: United States
Website: https://www.factmr.com